KALV
KalVista Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.37B
5Y Perf.+137.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KALV vs KALA
Revenue, margins, valuation, and 5-year total return — side by side.
KALA
KALA BIO, Inc.
Biotechnology
Market Cap$618K
5Y Perf.-100.0%
KALV vs KALA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KALV | KALA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.37B | $618K |
| Revenue (TTM) | $15M | $254K |
| Net Income (TTM) | $-210M | $-36M |
| Gross Margin | -17.2% | -3.1% |
| Operating Margin | -13.4% | -150.6% |
| Total Debt | $6M | $32M |
| Cash & Equiv. | $99M | $51M |
KALV vs KALA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KALV
KALA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| KalVista Pharmaceut… (KALV) | 100 | 237.5 | +137.5% |
| KALA BIO, Inc. (KALA) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KALV vs KALA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KALV leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. KALA BIO, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
KALV
KalVista Pharmaceuticals, Inc.
The Income Pick
KALV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.82
- 154.5% 10Y total return vs KALA's -100.0%
- Lower volatility, beta 0.82, Low D/E 6.6%, current ratio 5.35x
Best for: income & stability and long-term compounding
KALA
KALA BIO, Inc.
The Growth Play
KALA is the clearest fit if your priority is growth exposure.
- Rev growth 262.9%, EPS growth 59.8%
- 262.9% revenue growth vs KALV's -34.5%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KALA | 262.9% revenue growth vs KALV's -34.5% |
| Quality / Margins | KALV | -13.9% margin vs KALA's -141.1% |
| Stability / Safety | KALV | Beta 0.82 vs KALA's 2.09, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KALV | +118.1% vs KALA's -97.6% |
| Efficiency (ROA) | KALV | -77.7% ROA vs KALA's -143.2% |
KALV vs KALA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKALVLAGGINGKALA
KALAKALA BIO, Inc.
0leads
KALVKalVista Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs KALAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KALV3/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KALV6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
KALV6/6
Risk & VolatilityBeta, volatility, and downside exposure
KALV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KALV leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KALV is the larger business by revenue, generating $15M annually — 59.5x KALA's $254,000. KALV is the more profitable business, keeping -13.9% of every revenue dollar as net income compared to KALA's -141.1%.
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $15M | $254,000 |
| EBITDAEarnings before interest/tax | -$202M | -$38M |
| Net IncomeAfter-tax profit | -$210M | -$36M |
| Free Cash FlowCash after capex | -$160M | -$32M |
| Gross MarginGross profit ÷ Revenue | -17.2% | -3.1% |
| Operating MarginEBIT ÷ Revenue | -13.4% | -150.6% |
| Net MarginNet income ÷ Revenue | -13.9% | -141.1% |
| FCF MarginFCF ÷ Revenue | -10.6% | -126.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -1.1% | +44.6% |
KALV leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
Evenly matched — KALV and KALA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Market CapShares × price | $1.4B | $617,676 |
| Enterprise ValueMkt cap + debt − cash | $1.3B | -$18M |
| Trailing P/EPrice ÷ TTM EPS | -7.24x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 13.91x | 0.04x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KALV and KALA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
KALV leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
KALV delivers a -2.8% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-4 for KALA. KALV carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to KALA's 2.62x.
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.8% | -3.9% |
| ROA (TTM)Return on assets | -77.7% | -143.2% |
| ROICReturn on invested capital | -152.3% | — |
| ROCEReturn on capital employed | -89.9% | -95.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.07x | 2.62x |
| Net DebtTotal debt minus cash | -$92M | -$19M |
| Cash & Equiv.Liquid assets | $99M | $51M |
| Total DebtShort + long-term debt | $6M | $32M |
| Interest CoverageEBIT ÷ Interest expense | -13.75x | -6.92x |
KALV leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
KALV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KALV five years ago would be worth $10,595 today (with dividends reinvested), compared to $3 for KALA. Over the past 12 months, KALV leads with a +118.1% total return vs KALA's -97.6%. The 3-year compound annual growth rate (CAGR) favors KALV at 41.0% vs KALA's -82.6% — a key indicator of consistent wealth creation.
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +72.8% | -86.6% |
| 1-Year ReturnPast 12 months | +118.1% | -97.6% |
| 3-Year ReturnCumulative with dividends | +180.1% | -99.5% |
| 5-Year ReturnCumulative with dividends | +5.9% | -100.0% |
| 10-Year ReturnCumulative with dividends | +154.5% | -100.0% |
| CAGR (3Y)Annualised 3-year return | +41.0% | -82.6% |
KALV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
KALV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KALV is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than KALA's 2.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KALV currently trades 99.5% from its 52-week high vs KALA's 0.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 2.09x |
| 52-Week HighHighest price in past year | $26.84 | $20.60 |
| 52-Week LowLowest price in past year | $9.83 | $0.08 |
| % of 52W HighCurrent price vs 52-week peak | +99.5% | +0.4% |
| RSI (14)Momentum oscillator 0–100 | 75.4 | 30.1 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 9.2M |
KALV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KALV as "Buy" and KALA as "Buy". Consensus price targets imply 21861.5% upside for KALA (target: $18) vs 6.7% for KALV (target: $29).
| Metric | KALVKalVista Pharmace… | KALAKALA BIO, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.50 | $18.25 |
| # AnalystsCovering analysts | 13 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KALV leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallKalVista Pharmaceuticals, I… (KALV)Leads 4 of 6 categories
Loading custom metrics...
KALV vs KALA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KALV or KALA a better buy right now?
Analysts rate KalVista Pharmaceuticals, Inc.
(KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KALV or KALA?
Over the past 5 years, KalVista Pharmaceuticals, Inc.
(KALV) delivered a total return of +5. 9%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: KALV returned +154. 5% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KALV or KALA?
By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.
(KALV) is the lower-risk stock at 0. 82β versus KALA BIO, Inc. 's 2. 09β — meaning KALA is approximately 154% more volatile than KALV relative to the S&P 500. On balance sheet safety, KalVista Pharmaceuticals, Inc. (KALV) carries a lower debt/equity ratio of 7% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KALV or KALA?
On earnings-per-share growth, the picture is similar: KALA BIO, Inc.
grew EPS 59. 8% year-over-year, compared to -7. 3% for KalVista Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KALV or KALA?
KalVista Pharmaceuticals, Inc.
(KALV) is the more profitable company, earning -1391. 1% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps -1391. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KALV leads at -1343. 0% versus -150. 6% for KALA. At the gross margin level — before operating expenses — KALA leads at -3. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KALV or KALA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KALV or KALA better for a retirement portfolio?
For long-horizon retirement investors, KalVista Pharmaceuticals, Inc.
(KALV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82), +154. 5% 10Y return). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KALV: +154. 5%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KALV and KALA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.